BridgeMD
Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV
EU CTIS ID: 2025-524978-42-00
What this study is testing
To evaluate the efficacy (microbiological cure rate) of a 7-day course of doxycycline 200 mg daily orally for the treatment of asymptomatic anal LGV infection, four weeks after treatment initiation.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Free written informed consent signed by the participant or by an impartial witness (in the event of the participant’s inability to write) or by a legal representative (in the event of the participant’s inability to consent) and the investigator (no later than the day of inclusion and before any examination required by the research).
- Male sex at birth
- LGV-positive result on anal specimen using Nucleic Acid Amplification Test at screening
- Having taken at least doxycycline for two days (i.e 400 mg of doxycycline)
- Not having taken more than 7 days of doxycycline 200 mg per day
You likely can't join if
- Individual with proctitis
- Antibiotic treatment with antichlamydial activity (fluoroquinolones, macrolides–lincosamides–streptogramins–ketolides, tetracyclines and rifampicin) within 28 days at the screening visit
- Use of doxycycline post-exposure prophylaxis (Doxy-PEP)
- Participation in another study evaluating an antibiotic for STIs or other types of infection
- Individual under a measure of legal protection measure (safeguard of justice, guardianship or curatorship) or unable to consent
- Refusal to participate in the study
See the full eligibility criteria
- Age ≥ 18 years
- Free written informed consent signed by the participant or by an impartial witness (in the event of the participant’s inability to write) or by a legal representative (in the event of the participant’s inability to consent) and the investigator (no later than the day of inclusion and before any examination required by the research).
- Male sex at birth
- LGV-positive result on anal specimen using Nucleic Acid Amplification Test at screening
- Having taken at least doxycycline for two days (i.e 400 mg of doxycycline)
- Not having taken more than 7 days of doxycycline 200 mg per day
- No more than 12 days between the date of screening and date of inclusion
- No anorectal symptoms
- Individual available for participation and follow-up during the four weeks required for the study
- Affiliate or beneficiary of a social security scheme
- Individual with proctitis
- Antibiotic treatment with antichlamydial activity (fluoroquinolones, macrolides–lincosamides–streptogramins–ketolides, tetracyclines and rifampicin) within 28 days at the screening visit
- Use of doxycycline post-exposure prophylaxis (Doxy-PEP)
- Participation in another study evaluating an antibiotic for STIs or other types of infection
- Individual under a measure of legal protection measure (safeguard of justice, guardianship or curatorship) or unable to consent
- Refusal to participate in the study
- Objectives of the study not understood
- Participant detained by judicial or administrative decision
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.